Found the article below on the UBI thread - Wilson HTM analyst...

Found the article below on the UBI thread - Wilson HTM analyst believes NAN is closer to turning a maiden profit than UBI (sometime this FY).

I have c&p the article as it has info for NAN s/holders :)

"
Universal Biosensors (UBI)

The medical equipment maker’s fall from grace is another that doesn’t appear linked to its results.

The stock lagged the market by over 6% on its half year result on August 1, and has struggled to recover since.

There was nothing sinister in the profit numbers or outlook from the maker of disposable test strips used in LifeScan’s (which is a Johnson & Johnson company) blood glucose machine.

WilsonHTM Investment Group analyst, Shane Storey, believes that investors may be selling out of Universal Biosensors and jumping into fellow medical equipment maker Nanosonics (NAN), which is up 16% since its results.

This is because Nanosonics is closer to turning in a maiden profit. It should hit that important re-rating milestone sometime this financial year, while Universal Biosensors is not anticipated to cross that line until next year, or the year after.

However, Storey believes there is a near-term catalyst for Universal Biosensors, which could come later this month, and he anticipates that the stock could double in value over the next 12-months.

“We must be very close now to Siemen’s launching Universal Biosensors’ second product,” said Storey. “I am hoping that the news will add a whole new dimension to the way people think about the company.”

Siemens has signed an agreement with Universal Biosensors to use its technology to make a blood coagulation testing device. The deal is similar to the deal with LifeScan and Universal Biosensors believes the coagulation opportunity can generate as much value as glucose. "

- I must say that I was considering splitting my investments across NAN and UBI earlier this year, but went the whole hog to NAN based on my belief that NAN is better protected against competition and has a unique offering compared to UBI, where the current testing is crowded with large pharma and therefore greater competition albeit the market is much larger than that being addressed by NAN.

Wouldn't mind adding some UBI to my holdings if some other energy plays come good.

GLTAH